10-Q quarterly report · filed Nov 9, 2026

ADC Therapeutics SA (ADCT) Q3 2026 10-Q Quarterly Report

Short answer

ADC Therapeutics SA (ADCT) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $21M (up 33.4% year over year) with net income of −$25M.

Q3 2026 key financials · XBRL

Revenue
$21M
+33.4% YoY · +12.7% QoQ
Net income
−$25M
+38.2% YoY · −52.8% QoQ
Operating margin
-68.3%
EPS (diluted)
−$0.16
+42.9% YoY · −45.5% QoQ

Source: XBRL data from the ADC Therapeutics SA (ADCT) Q3 2026 10-Q on SEC EDGAR. USD.

ADC Therapeutics SA Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $21.7M, up 32.2% YoY from $16.4M, driven by ZYNLONTA product revenue of $21.0M, up 33.4%
  • Operating margin 66.1% loss vs 188.6% loss YoY, with operating loss $14.4M vs $31.0M
  • Best performer: ZYNLONTA product revenue $21.0M vs $15.8M, up 33.4%; license revenue $0.7M in both periods
  • Nine-month operating cash use $69.4M vs $110.1M; cash and equivalents $189.2M at September 30
  • October financing raised $76.3M; $70.0M term-loan prepayment reduced outstanding principal to $50.0M
  • Outlook: fiscal 2026 R&D expense expected to decrease; headwinds include inflation, tariffs and ongoing royalty and debt obligations

Risk Factors

  • Newly added LOTIS-5 regulatory risk: FDA cited increased Grade 5 adverse events and marginal benefit
  • Most material update: Potential withdrawal of ZYNLONTA’s accelerated 3L+ DLBCL approval
  • Compliance risk: Confirmatory trial required to verify clinical benefit and maintain current approval
  • Operational risk: LOTIS-5 results may impair enrollment in other ZYNLONTA trials
  • Commercial risk: Negative benefit-risk perception could reduce ZYNLONTA sales

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ADC Therapeutics SA quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.